<SUBMISSION>
<ACCESSION-NUMBER>0001023024-05-000014
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050812
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20050812
<DATE-OF-FILING-DATE-CHANGE>20050812
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>BIOSANTE PHARMACEUTICALS INC
<CIK>0001023024
<ASSIGNED-SIC>2836
<IRS-NUMBER>582301143
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31812
<FILM-NUMBER>051020545
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
<PHONE>8474780500
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>BEN ABRAHAM TECHNOLOGIES INC
<DATE-CHANGED>19991027
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>q2-2005pressrelease.htm
<DESCRIPTION>BIOSANTE 8K FOR 2ND QUARTER RESULTS
<TEXT>
<html>
  <head>
    <title>
      BioSante 8K for 2nd quarter results
</title><!-- Licensed to: BioSante Pharmaceuticals-->
<!-- Document Created using EDGARIZER HTML 3.0.0.25799 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body>
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div>
          <div>
            <hr style="COLOR: #000000" align="left" noshade size="5" width="100%">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman, serif"><strong>UNITED
        STATES</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman, serif"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">__________________</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif"><strong>FORM
        8-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>Current
        Report</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>Pursuant
        to Section 13 or 15(d) of the Securities Exchange Act of
        1934</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">__________________</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Date
        of Report (Date of earliest event reported): </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>August&#160;12,
        2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman, serif"><strong>BIOSANTE
        PHARMACEUTICALS, INC.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Exact
        name of registrant as specified in its charter)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>Delaware</strong></font></div>
              </td>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>1-31812</strong></font></div>
              </td>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>58-2301143</strong></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(State
                  or other jurisdiction of incorporation)</font></div>
              </td>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Commission
                  File Number)</font></div>
              </td>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(I.R.S.
                  Employer Identification Number)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>111
                  Barclay Boulevard</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>Lincolnshire,
                  Illinois</strong></font></div>
              </td>
              <td valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>60069</strong></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Address
                  of principal executive offices)</font></div>
              </td>
              <td valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Zip
                  Code)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>(847)
        478-0500</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Registrant&#8217;s
        telephone number, including area code)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>N/A</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Former
        name or former address, if changed since last report)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">Check
        the appropriate box below if the Form 8-K filing is intended to simultaneously
        satisfy the filing obligation of the registrant under any of the following
        provisions:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">[
        ] Written communications pursuant to Rule 425 under the Securities Act (17
        CFR
        230.425)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">[
        ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
        CFR
        240.14a-12)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">[
        ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
        Act (17 CFR 240.14d-2(b))</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">[
        ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
        Act (17 CFR 240.13e-4(c))</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div><br>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div style="WIDTH: 100%" align="left">
            </div>
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
            <div style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 81pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><strong>Section&#160;2
        &#8212; Financial Information</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><strong>Item
        2.02</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 36pt">&#160;</font>&#160;<font id="TAB2" style="COLOR: black; LETTER-SPACING: 4.5pt">&#160;&#160;&#160;</font>&#160;<font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><strong>Results
        of Operations and Financial Condition</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;On&#160;August
        12,
        2005, BioSante Pharmaceuticals, Inc. publicly announced its financial results
        for the&#160;second quarter ended&#160;June 30, 2005.&#160; For further
        information, please refer to the press release attached hereto as Exhibit
        99.1,
        which is incorporated by reference herein.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;The
          information contained in this report and the exhibit hereto shall not be
          deemed
          to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934,
          as amended, and shall not be incorporated by reference into any filings
          made by
          BioSante Pharmaceuticals, Inc. under the Securities Act of 1933, as amended,
          or
          the Exchange Act, except as may be expressly set forth by specific reference
          in
          such filing. </font><br></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><strong>Section
        9 &#8212; Financial Statements and Exhibits</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><strong>Item
        9.01</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 36pt">&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><strong>Financial
        Statements and Exhibits</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div>
        <table border="0" cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 72pt"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(c)&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">Exhibits.</font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 4.3pt" align="justify"><br></div>
      <div>
        <table border="1" cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td valign="top" width="11%" style="BORDER-BOTTOM: black thin solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><strong>Exhibit
                  No.</strong></font></div>
              </td>
              <td valign="top" width="60%" style="BORDER-BOTTOM: black thin solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><strong>Description</strong></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="11%" style="BORDER-BOTTOM: black thin solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">99.1</font></div>
              </td>
              <td valign="top" width="60%" style="BORDER-BOTTOM: black thin solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">Press
                  release issued&#160;August 12,
                  2005.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div style="WIDTH: 100%" align="left">
          </div>
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
          <div style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>SIGNATURE</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant
        has
        duly caused this report to be signed on its behalf by the undersigned hereunto
        duly authorized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>BIOSANTE
        PHARMACEUTICALS, INC.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font size="2">&#160;</font></td>
              <td width="1%"><font size="2">&#160;</font></td>
              <td width="49%"><font size="2">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font size="2">&#160;</font></td>
              <td colspan="2">&#160;</td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font size="2">&#160;<br>&#160;</font></td>
              <td><font size="2">&#160;<br>&#160;</font></td>
              <td><font size="2">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font size="2">Date:&#160;August 12, 2005</font></td>
              <td><font size="2">By:&#160;&#160;</font></td>
              <td><font size="2">/s/ Phillip B. Donenberg</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%">
              </td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font size="2">&#160;</font></td>
              <td><font size="2">Chief Financial Officer, Treasurer, and
                Secretary</font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div style="WIDTH: 100%" align="left">
          </div>
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
          <div style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>BIOSANTE
        PHARMACEUTICALS, INC.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>FORM
        8-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><strong>EXHIBIT
        INDEX</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Exhibit
        No.</u></strong>&#160;&#160;&#160;&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;<u>&#160;&#160;&#160;</u></font><strong><u>Description&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;</u>&#160;&#160;&#160;&#160;&#160;&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;&#160;<u>&#160;&#160;
        Method of Filing<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</u><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="justify">99.1&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font>Press
        Release issued&#160;August 12,
        2005&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Filed
        herewith</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 36pt" align="justify">&#160;</div>
    </div>
  </body>
</html>







</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease8-12.htm
<DESCRIPTION>PRESS RELEASE DATED 8-12-2005
<TEXT>
<html>
  <head>
    <title>
      Press release dated 8-12-2005
</title><!-- Licensed to: BioSante Pharmaceuticals-->
<!-- Document Created using EDGARIZER HTML 3.0.0.25799 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;

    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><strong>BioSante
      Pharmaceuticals, Inc.&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><strong>FOR
      IMMEDIATE RELEASE&#160;</strong></font>&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: Times New Roman, serif"><strong>
      Amex: BPA</strong></font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><strong><img src="biosantelogo6.jpg" alt=""><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;</strong></font><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>BioSante
        Pharmaceuticals Reports Product Development Highlights </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>and
        Second Quarter 2005 Financial Results </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>LINCOLNSHIRE,
        Illinois (August 12, 2005) -</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        BioSante
        Pharmaceuticals</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (AMEX:
        BPA) today reported on certain product development highlights and announced
        financial results for the second quarter ended June 30, 2005. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Our
        positive topline data from the Bio-E-Gel</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#8482;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase
        III
        trial and progress made with our CaP nanotechnology program drove this
        successful quarter for BioSante,&#8221; said Stephen M. Simes, BioSante&#8217;s president
        and chief executive officer. &#8220;We plan to present full Bio-E-Gel data at a
        medical meeting this fall, with publication in a peer-reviewed journal to
        follow. Currently, we are preparing a New Drug Application for submission
        to the
        U.S. Food and Drug Administration for Bio-E-Gel, and anticipate initiating
        Phase
        III LibiGel</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#8482;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        studies
        by year end.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Product
        and Corporate Highlights</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;&#160;&#160;</font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
                  announced significant safety and efficacy results of its 12-week,
                  randomized, double-blind, placebo-controlled Phase III clinical
                  trial of
                  Bio-E-Gel (bioidentical estradiol transdermal gel) for the treatment
                  of
                  moderate-to-severe hot flashes in menopausal women. The 484-patient
                  study,
                  which included three doses of Bio-E-Gel to maximize the safety
                  profile by
                  identifying the lowest effective dose, had four co-primary endpoints
                  of a
                  significant decrease over placebo in both the number and severity
                  of hot
                  flashes at Week 4 and Week 12 of treatment. By Week 4, the mid
                  and high
                  doses of Bio-E-Gel showed highly significant decreases in the number
                  and
                  severity of hot flashes versus placebo (p&lt;0.0001), a response that was
                  maintained until Week 12. At Week 5, the low dose showed a highly
                  significant decrease in the number (p&lt;0.001) and severity (p&lt;0.01)
                  of hot flashes verses placebo. These significant responses were
                  maintained
                  through Week 12 (p&lt;0.0001), therefore suggesting identification of the
                  lowest effective dose. There were no significant differences in
                  the safety
                  profile of any dose of Bio-E-Gel compared to placebo.
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><strong>&#183;&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
                  Company presented a review of progress toward the use of
                  BioVant</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#8482;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
                  BioSante&#8217;s patented calcium phosphate (CaP) nanoparticle technology, in
                  viral and bacterial vaccine candidates at the International Conference
                  on
                  Immunopotentiators in Modern Vaccines in Spain. BioSante also presented
                  BioVant data at the annual World Vaccine Congress in Montreal,
                  focusing on
                  the intranasal mucosal surface delivery of an anthrax vaccine,
                  and
                  highlighting the simultaneous immune adjuvant effects and non-injected
                  vaccine delivery potential of
                  BioVant.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><strong>&#183;&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
                  announced a new manufacturing agreement with a U.S.-based current
                  good
                  manufacturing practices (cGMP) manufacturer for large-scale quantities
                  of
                  CaP nanotechnology. </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top" style="LINE-HEIGHT: 1.25">
              <td align="right" style="WIDTH: 36pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif"><strong>&#183;&#160;&#160;</strong></font></td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
                  was added to the Russell Microcap</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#8482;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                  Index, which measures the performance of the microcap segment and
                  includes
                  the smallest 1,000 securities in the small-cap Russell 2000 Index
                  plus the
                  next 1,000 securities, based on descending market capitalization.
                  As of
                  the latest reconstitution, the average market capitalization of
                  the Index
                  was approximately $217 million. </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Second
        Quarter 2005 Financial Overview </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
        incurred a net loss of approximately $2.58 million, or $(0.13) per basic
        and
        diluted share for the quarter ended June 30, 2005, compared to a net loss
        of
        approximately $2.57 million, or $(0.15) per basic and diluted share for the
        second quarter of 2004. For the first six months of 2005, the Company&#8217;s net loss
        totaled approximately $5.35 million, or $(0.28) per basic and diluted share,
        compared to a net loss of approximately $5.02 million, or $(0.32) per basic
        and
        diluted share, for the first six months of 2004. As of June 30, 2005, the
        Company&#8217;s cash, cash equivalents and short-term investments were approximately
        $12.1 million. The Company anticipates a cash burn rate of approximately
        $750,000 per month for the remainder of 2005.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -4.5pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -4.5pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
        BioSante Pharmaceuticals, Inc. </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -4.5pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
        is developing a pipeline of hormone therapy products to treat both men and
        women. These hormone therapy products are gel formulations for transdermal
        administration that deliver bioidentical estradiol and testosterone. BioSante&#8217;s
        lead products include Bio-E-Gel</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#8482;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (bioidentical estradiol gel) for the treatment of women with menopausal
        symptoms, and LibiGel</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#8482;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (bioidentical testosterone gel) for the treatment of female sexual dysfunction
        (FSD). The current market in the U.S. for estrogen and testosterone products
        is
        approximately $2.5 billion. The transdermal gel formulations used in the
        women's
        gel products are licensed by BioSante from Antares Pharma Inc. (Amex: AIS).
        The
        company also is developing its calcium phosphate nanotechnology (CaP) for
        novel
        vaccines, including biodefense vaccines for toxins such as anthrax and ricin,
        and drug delivery systems. Additional information is available online at
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.biosantepharma.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>This
        news release contains forward-looking statements within the meaning of the
        Private Securities Litigation Reform Act of 1995. The statements regarding
        BioSante contained in this press release that are not historical in nature,
        particularly those that utilize terminology such as "may," "will," "should,"
        "likely," "expects," "anticipates," "estimates," "believes" or "plans," or
        comparable terminology, are forward-looking statements. Forward-looking
        statements are based on current expectations and assumptions, and entail
        various
        risks and uncertainties that could cause actual results to differ materially
        from those expressed in such forward-looking statements. Important factors
        known
        to BioSante that cause actual results to differ materially from those expressed
        in such forward-looking statements are the difficulty of developing
        pharmaceutical products, obtaining regulatory and other approvals and achieving
        market acceptance, and other factors identified and discussed from time to
        time
        in BioSante's filings with the Securities and Exchange Commission, including
        those factors discussed on pages 19 to 31 of BioSante's Form 10-KSB, which
        discussion also is incorporated herein by reference. </em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>All
        forward-looking statements speak only as of the date of this news release.
        BioSante undertakes no obligation to update or revise any forward-looking
        statement, whether as a result of new information, future events or
        otherwise.</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        more information, please contact: </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phillip
        Donenberg, BioSante Pharmaceuticals, Inc.; (847) 478-0500;
        donenber@biosantepharma.com</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ritu
        S.
        Baral, The Trout Group LLC; (212) 477-9007 ext 25;
        rbaral@troutgroup.com</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Daniel
        Budwick, BMC Communications; (212) 477-9007 ext 14; </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>dbudwick@bmccommunications.com</u></font></div>
    </div>
  </body>
</html>







</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>biosantelogo6.jpg
<DESCRIPTION>BIOSANTE LOGO
<TEXT>
begin 644 biosantelogo6.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"/`5(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#S?_A-/%?_
M`$,VL_\`@?+_`/%4'QKXK'_,S:U_X'R__%5A4'I7UWLX=D(]4T_PU\6=4TZU
MO[76]1:WN(EFC<ZP>C?,,C?Z5/\`\(7\8O\`H+ZA_P"#IO\`XNO9O`9SX!\/
M$\G^S;?G_@`J]J'B'1](=4U/5K&R=QN5;FY2,M],FO`EC:BFXJ*T\AGA?_"%
M_&+_`*"^H?\`@[;_`.+I&\&_&5!QJ6J2?36L?^SU[5_PF_A7_H9M&_\``^/_
M`!J>R\3:#J<HAL-;TRYD)QM@NXW;\@33>-K+>*_\!)LCYNUG_A9_AV)I-6OO
M$EO&HYF^W2/&OU=6V_\`CU87_":^*_\`H9M9_P#`^7_XJOL-X8I$9'C5D;[R
MLN0?J*^7/BMX.@\(^*`;)%CL+Y3-#$3PA'WU'H.5Q_O>U=>$QD:SY)Q28[%W
M0M(^*7B72H]2TS7-2FM9&*ASJ[*?E]O,JMXEC^(WA*&";6->U6);ABD6W5'?
MISV<=J]-^$>NZ19?#VU@O-5L;>59I,I+<(C8)X^\U<]\==7TS5--T9+'4;2[
MV3NS"WF63:-O7AJBG7J2Q'LW%6]`L>7_`/":^*_^AFUG_P`#Y?\`XJC_`(33
MQ7_T,VL_^!\O_P`56%17K>SAV0&[_P`)IXK_`.AFUG_P/E_^*H_X33Q7_P!#
M-K/_`('R_P#Q585%'LX=D!N_\)KXK_Z&;6?_``/E_P#BJ/\`A-?%7_0SZS_X
M'R__`!587UK;\'^'I/%7BFPT@$A)7S*0,8C'+?CBE-4X1<FEH!IZ3JOQ"U^;
MRM)U;Q%>/GDPW<K*OU;<%%=7%X/^,;KN;4=5CS_#)K?/Z/7O>EZ39Z+IT6GV
M%O'!;QKM"#O[D]S]:9J.M:9I$8;4-3L[0'^*YG6//YUX<\?)R_=P5O0+'A/_
M``A?QB_Z"^H?^#MO_BZ/^$+^,7_07U#_`,';?_%U[3_PF_A7_H9M&_\``^/_
M`!H_X3;PK_T,VC?^!\7^-+ZY6_D7W"LCQ8>"_C$2!_:^H<_]1MO_`(NN)U#Q
M/XRTW4)[&Z\1:PDT#F.1!J,IY'H=U?3X\;>%,_\`(S:-_P"!T?\`C7RIXKFB
MN_%VK2V[QS1/=,RO&=P(]0177@:LZT^6I%?<.Q)_PFOBO'_(S:S_`.!\O_Q5
M'_":>*_^AFUG_P`#Y?\`XJL*BO3]G#L@-W_A-/%?_0S:S_X'R_\`Q5'_``FG
MBO\`Z&;6?_`^7_XJL*BCV<.R`W?^$T\5_P#0S:S_`.!\O_Q5'_":>*_^AFUG
M_P`#Y?\`XJL*BCV<.R`W?^$T\5_]#-K/_@?+_P#%4?\`":>*_P#H9M9_\#Y?
M_BJPJ*/9P[(#=_X33Q7_`-#-K/\`X'R__%4?\)IXK_Z&;6O_``/E_P#BJPJ*
M/9P[(#=_X37Q5GGQ-K.._P#I\O\`\57<:?X9^+.K:;;:A::UJ+VUU$LT3?VN
MPRK#(_C]Z\JK[!\"`?\`"O\`P]Q_S#H/_0!7!CZOL$N1+7R%$^<?$&I>//"V
MIG3M6\0ZM%=>6'`35'88)SZ^E9)\:>*_^AFUG_P/E_\`BJZWXY<?$1L<?Z+%
M_6O-:ZL.HU*49M*XS=_X33Q7_P!#-K/_`('R_P#Q5'_":>*_^AFUG_P/E_\`
MBJPJ*U]G#L@-W_A-/%?_`$,VL_\`@?+_`/%4?\)IXK_Z&;6?_`^7_P"*K"HH
M]G#L@-W_`(33Q7_T,VL_^!\O_P`50?&OBO'_`",VM?\`@?+_`/%5A4'I0Z<.
MR`^TO#TLDWAK2I97:21[.%G=SDL2@))/<T4WPU_R*NC_`/7E#_Z`**^3G\3&
M?%]!Z44'I7UXC[!\"?\`)/\`P]_V#;?_`-%BO(/VA?\`D/:(>_V:4_\`CU>O
M^`_^1`\/?]@VW_\`0!6?XO\`ASH_C6ZM+G5)KR-[9"L8MI%'!]=RFOF:-6-'
M$.<MD,^3MH]!3E=XG$B,R.ARK*<$'V-?1_\`PH3PC_S]:M_X$)_\15BP^"/@
M^PO5N"M]=[.1!<3`I^(503^=>I/-*#6E_N%8[/PU<W-YX6TFZNRQN9K*&24G
M@LYC4GZ<UY#^T*Z9\/PX!FS,PYZ+\O\`];\C7L>J:K8:!IDEY?SI;6L(^9V[
M>@P*^5O'OBV7QEXEDU'8Z6L:&*UC/41]C]3D_E7!E]-SKJ:V0I'9^!/A#I?B
MWPI!K-SJ%W#/+(X*QHI'!QT-9/Q-^'%CX&M=/FLKNXG-T[QL)5`Q\OM7K7P6
M`_X5M9#`_P!?+_.N:_:%`&F:&<?\O#_^@UO3Q-5XODYM+VL,\%->D^$/@[J_
MB.WCO[^4:;8N`8RZYDE'J%[?C^M0_"+PA#XD\5&YOH=UCIX$KHXR)'/W`1Z<
MYQ[5]*7][:Z78S7MU(L5O"A=V/8"ML;C94Y>RI;]PL>:Q?`/PI''^]N]7E?N
MWG(/TV5EZO\``&Q>-VT;5KF*3^&.\"NK_BHR/RK+U3X^Z@]\W]D:3;BV1L*;
MG<TCCUPO`KN?A]\3K;QI(]C<V_V+4D'F>6&W)*OJI_I7)+Z[3C[63T%H?.WB
M#P[J?A?4FT_5+1H9NJ=U<?WD/<>QKO?@/#')XYN9&P3'9N5R.F2!_(FO8?B%
MX1M_%WA:XM&C'VN)6EMI".5<=OQKP/X6Z]%X=^(%J]X1%#<!K>7<,;">!GZ'
MK76L2\3A9I[H=CZGN7:*UFD099$9E'N!7Q;J=_=:KJUS?WDC27,DC,2_)7D\
M9/85]J'YAZ@CH.017FNL_!3PSJVHS7<<MY9R2L6DCA92ASZ`CBO/P.(IT)/G
MZC/FC`]!1A?05]#_`/#/V@_]!;4?R3_"D?\`9^T(J<:OJ`]\)_A7J_VG0[L#
MYYVC^Z/RI<#@=NPKUWQ#\"=1TZUDN=%OTU':,^3*HBDQ['.TUY'+%)!-)%*C
M+(C89&&"I[@UTT<13K?PV(]6^'OPHT[QEX535;K4+NWF,SQ%8T!'RGWKJ_\`
MAGS1?^@S?_\`?"UYWX/^*VH^#="_LNTTZTN(Q*\F^20CD\UT'_#0.M_]`33\
M^OFM7GU88YS?(]`.B/[/NB@'_B<ZAT_N+6)K'P!O(8'DT75TNG`R(;F(Q[O8
M,,C/Y4V+]H+5DD7S]!M&3IA9F4GZ96O7_"?B:S\8Z%#JEHCHK$JT;CF-AU'O
M7-.KC*'O5'H,^1+RSN=.OI;.\@>&XB8J\;+\P(_I[UU'PZ\(6WC/Q#)IMW<S
M6\2VYF#Q`$G!`[_6N^^/VBQ))I>MQ18EDW03'U`P5SZ]36'\!O\`D>[DXR?L
M3_\`H2UZ$L3*>$]K'1BL=C_PSYHG_0:U#_OE/\*/^&?-$Y_XG6H?]\I_A7I7
MB36#H'AV^U18?/:TB\P1EMN[G&,UX^/VB+C_`*%>+_P./_QNO,I5,953<&W8
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MD3MC=%:P%]O_``-F'/T%=Y\*_"<?AKPA;221XO[Y!<7+G[PR/E3/LN./7)J'
MX@?$ZV\%7$-A%9M>ZA-'YWE%MJQKR,L:FMC*U2K[.B!@#]GW10/FUK4&/KY:
MC^E17?P"T:"SGF76+XM'&S@,BXR!GFL(_M!ZPQ.-"LU`/>5S_P"RTR?X^ZK/
M;2PMHEHJNC*2)6R,C&?NTU3QU]63H>1##X;/!!/3'KC^5!Z&E"E!M(Q@;>N>
MA(/\Z0CBO:7PZC/M#PU_R*NC_P#7E#_Z`**/#7_(JZ/_`->4/_H`HKY&I\;&
M?%]!Z44'I7UPC[!\!_\`(@>'O^P;;_\`H`K!\?\`Q*B\"7]E:R:=)>&ZC:0%
M9`NW:W-;W@/_`)$#P]_V#;?_`-`%>0_M`1/)K^C&.-W7[+*"54G'S=\"OF:%
M.%3$\L]AFG_PT-!_T+\G_@2O^%6;+]H#3+BZ6.]T:Y@A;K)'(),?45X'Y,O_
M`#SD_P"^#5F#2[^_NEMK:TN)IY6VJJ1L2WX$<?C7K3P&%4?^"*Y]F$6>J:>-
MRQW5I<("`RAE=6Z<'BOF;XJ^#+?PAXCC-DNW3[Y#+$A))B9?OKG_`($N/][V
MKZ,\,Z?-I/A?2M/N,":WM(HY,'(W*H#8_&O*?VA7C%GH,;<2F29A_NJ!_4K7
MF8&<HXA16S&=5\%N/AK9?]=I?YUS7[0W_(,T+_KX?_T&NE^"_P#R36R_Z[2_
MSKFOVAO^09H7_7P__H-72_W[YB+7P!M8XO"VI70_UDMT%8_[J\?^A&M/XX7<
MMM\/7AC.U;BYCB<C^[G)_/'ZUSW[/NJ1M9ZQI3,/,619T7N1T8_GBNV^*7A^
M?Q#X#O;:VCWW,)%Q&O\`>*G)7ZD9%35]W&7EW`^4\5T?@"[DLO'FARQMRUVB
M'`QP3S7.N"K%2""#A@1@JWH0:[OX2^'9]:\;V5RL9^RV,OGRR8^7(Y"_GBO;
MQ$HJE)R86/J;`%?&OBJ$6WC#5X4X5;V0?FQ:OL6>=+6WDGE8*D:EF).,`"OB
M_6+O^U=>OKQ?F%S<22Q@@Y(+?*..^*\G*HOGD^@I'=^&/C'XAT"VCM+M(]3M
M8AA1.VR11Z;QU_$5V$?[0ED5'FZ!<@GLLJFO"_*G_P">$G'^R>*/*GSS!)_W
MP:]">!PTW=K\1GO/_#0FF?\`0!O/^_J?XU=TGX[Z%?7B6]WI]Y9+(VT3$JZ`
MD]R#D5\\^3/_`,\)/^^#5_2M`U/6[^.RL;&>69VQCRV^4>I.!C'UK*>`PRC?
M]0N?9B.K`.K`A@"".^>E?,GQIT>/2_'[W$*K''?0K,5QQO'#'^5?2=C`;33[
M6W?YGBA2,GU(`']*^?\`X_3))XKL8$8;X;,[Q[$YKS<O;C7T&RIX`^$T_BNT
M74]0N&LM-=CY2H/WDH'4C/`'O7IUO\$?!L2`/!>3^\D^?Y`5VF@6<-GX>T^W
MB4*B6T:C`P/N@UY'\4_B5XAT+Q7)HVDS):Q0Q(YD\L,[EAGO5^VQ&)J\L)6`
M[`?!?P2IS_9TPQ_T\-_C73^'?#&E^%;!K+287B@9BY#N6Y/UKYK_`.%N>.#Q
M_;;?]^(_\*]H^$7B35/$_ANZO-5NS<3I<&-6*A1C`[`48K#XFG"]65UZ@97Q
M\'_%(6/'_+X/Y&N(^`W_`"/5S_UY/_Z$M=Q\?/\`D4;'_K\_H:X?X"_\CW<_
M]>3_`/H2UM1_W&0CVGXBC_BWFN<#_CV/\Q7R*.*^N_B+_P`D]US_`*]C_,5\
MB5KE/P2%(]F_9ZR=5UW/_/"#_P!">O0?C"!_PK#5>!P8S]/G6O/OV>?^0KKO
M_7"#_P!">O0?C#_R3#5?K'_Z,6N?$_[ZOD,^5R/;M7V%X#_Y)_X=/?\`LZ#G
M_@"U\??X=Z^P/`7/P\\.GC_D&P?^@"M\W^"`HGA'QS`_X6&P_P"G6+^M><Q1
M"66.(\!V"?@37IWQXLY(/',%RZL(I[-2CXX)5BI7Z]_QKR[+)\Z\,OS#Z]JZ
M\(T\.DNPS[>C0)$J*,*!@5R7B'X:^'/$^JMJ.IV]Q)<2($)68J`!TXKH])OX
MM3T>SU"W<&&XA216]05S_6O)?BGX[\5^$/$R0V$D4>G36ZR0EXMP+9P1GU&"
M<>A%>#0A4E5Y:;LQG2#X)>#`,"UNL?\`7P?\*KWWP6\'0Z?<RQVMR'2)V4F<
M]0"1VKRK_A=OC3_G\L__``''^-,F^-/C&:"2*2[M"CJ58"``D$<]Z]%8;&7U
MG^(C@,\9!(#'</8<C]<4'H:4`C*_W3M(Z9.<_I2=C7LI>Z(^T?#7_(JZ/_UY
M0_\`H`HH\-?\BKH__7E#_P"@"BOD:GQLH^+Z#THH/2OKA'V#X#_Y$#P]_P!@
MVW_]`%;LEO#,P,L$;D<`L@.*^:=*U_7HM&LH[?7-0BB6%!'&CC:H].F<5;_X
M23Q%_P!##J/_`']7_P")KY^>!GSMW%SH^BOL=M_S[P_]\#_"G1P10Y,421[N
M3L4#-?.?_"2>(_\`H8=2_P"_J_\`Q--;Q%X@8;3X@U0CU\X#_P!EI?4:C^T'
M.CZ#O]2LM)M'NKZYBMX4&YI)6``_QKY=^)?C,>,_$OGV^X:=:H8[;/5Q_$Y'
M;=CI_LBH]7TZ^U0M)-J=U<R#H+F0L/P!Z5R<L3V\[QNI61>H-=^#P4:4N=N[
M"]SZ=^"P_P"+:V7_`%WE_G7-?M#?\@O0_P#KX?\`]!KS_P`-:UK-EHD<-IK%
M];6X9L1Q.`H_,52\8ZGJ>HPVBW^HW5WL8[?/<':?P`K.GA9+$^TOI>X^;6QF
M^%?$EWX3\0V^KV7.S(DC)QYL9^\I]_3Z5]4>&_%6D^*[!+K3;A7XR\3'YXSZ
M$?UKX\(W_*HSS72:+IM[93+>17EQ9SCH(6*OCT)'6M\9A(5?>O9DWL?2VJ?#
M_P`*ZS=M=WVB6TLY^\Z[E)/J<8%;&FZ3INAV?V;3[2&TMU&2L:X'U)[GZUXA
M;>.O$UM"L2ZM+*>FZ0*Q'Z5C:[K.M^((C'>ZU>[#_P`LU8(OXA:\Y8*K+W92
MT'SHZKXL?$FW-C-X=T6<2R2?+=7,;951_<!]3W/:O*?!*AO&^A(0"OVU/E(R
M.OI67?:?/82!95Q&?NLHXI=+EE@U:VEBD>*5)05=?X3_`(UZU+#QI4>2`7/M
M/[+;_P#/"+_O@4?9;?\`YX1?]\"OG4^)/$>?^1AU+_OZO_Q-)_PDGB/_`*&'
M4O\`OZO_`,37D?4JG\P<R/HO[+;_`//"+_O@4](TC7$:*H]%&*^<3XD\19_Y
M&'4?^_J__$U%/KOB"=&1O$&IX/<2X_D*/J$WU#F1[UX@\3:3X9L9+O4[N.)5
M&0A.78^@'6OE#Q7KTWBKQ%=ZM.K(+@D(I/W8QP!5K5-'N[EVNC>3W<GK/(6;
M'L37.LN/E*G*MSNKT<'@X4M6[L5^8^J?AMXPM/%'A>R02J+^WB$4\.[GY>,C
MVK;UGPCH'B"19-6TFWNI5P`[@AL>Y&*^5=#TZ[#K?1W4]J<X5H7*L?Q%=K'K
M_B!%"C7]3&.,^:#S^5<E7`6J-TY#YTCV/_A5W@D'/_".6O'N_P#C6WHOA_2_
M#UHUMI-BEI`SERD9)!/KS7@G_"2>(_\`H8M2_P"_J_\`Q-)_PD?B(#_D8=1`
M'_35?_B:RE@JLEK,.=';_'S_`)%"Q_Z_/Z&N(^`O_(]W'_7F_P#Z$M<_XNU;
M5;_3HX[[5+V[B$N0L[`J#CM@"LOPE>WUAK$CV5W-:2F(C?`P#8ST.17=3PS6
M%=.^XKZW/IWXB#_BWFN<?\NS?S%?(F.*]%UGQ!KUQHUW%<:Q?RPE,-'(Z_,/
M?`Z5YT1Q5X##NDFF]QWN>R_L\_\`(6UW_KA!_P"A/7H7QA_Y)CJOUC_]#6OG
MWP?J-_87=X=.OYK-I%`)A8`G!/7(K:\2:UK5UH=Q!=ZM>W%NY7,<SC:2/H*Q
MK824L3[2XN=(X`\`\9]O6OI+X.^+K;5/"UOHDTR+?V'[E49L>;&/ND?AQ^%?
M-N#VP#6KHNGW%Q,+N*:2V"$;9(V*L"/0CI77B\/&M3LV.]CZ[UC0-*U^W$&J
MZ?#=1J?E$@Z9]".?2O%/C)X.\/\`AK1--GT?3([.66X8,R;CD;1V)-9,.O:_
M!&J+X@U,(HQGS0?S)%8'B_5M2OK.U%_JEW=QI,2HE;(!QVP!7GX?"U(5$U+8
M.9'<?"3XDVVG6\?AO7)Q%&IQ9W).4'_3,GT'8_AZ5[5<V.FZY9@75M:WMN<E
M=ZB0<\9![?A7QK9:?+?2M'"H8+U)'`'N*[+25U31T"VVM:A",<I%*0H^@.:U
MQ.`BY\\)68<Z1]!'X>>$B<GP_9$GT0C^M5K_`.'WA2/3KITT"S5EA<@A3D$*
M?>O'QXD\18VCQ!J0`[F5?_B:9/XC\0M!*K:_J#*4(*F08(QT/RUS+"5D_C#F
M1YAG*].><=^,"D/0T`G;NY.0<C`'?K0>_%>\E[H7/M#PU_R*NC_]>4/_`*`*
M*/#7_(JZ/_UY0_\`H`HKY&I\;*/B^@T4&OKA';Z=_P`@RS./^6256U35GTZ6
M-!`CJR[LDU9T[_D&6G_7)*Q?$B,]U`R*Q&S^%<URQ492U,8_$+_PDLO_`#Z)
M_P!]4Z/Q/EE$MJ-O^R:PO*D_YY2?]^S3H[:>4JB0R_-_L5MR0*Y4=S&RR1AQ
M\RNNX$=JY_Q+"JSP3J!N?Y3[UNVD3P64$3D%XTV\5@^)95+V\2L-R_,U94_B
MT)C\1HZ%_P`@F,CU:J?BGF*#//S5<T+_`)!,?U:J?BC_`%,'^]50_B%?:*F@
MV23WCS.N4B7TXW5T]S<1VD$DTAPJ#-8_AM,6$K=RW-2>(79=,(`X=U6B>L[`
M]78RI]?O)9&9&1$[#&<5I:3K4EY-]GN0-_4$=#7,8Z\59L79-1MW7J)`#6DJ
M<4KE2BN4Z^_M4O;.6%NNWY3_`':XR"0V]R'9.4;)'TXKO<#GBN$OD"7\^T_\
MM#4T&3$USXE?_GV'YT'Q*W_/L/SK!"L3@#=3Q!,5SY,A7U$9JO9Q'9&V?$K\
M_P"C#\ZF@\2H\BK-;,H[$'I7/FWG'_+"3_OD_P"%2V]A=SR*B0R`'N4QBIY(
MBY4=OC+;L[E(SD5R>OVZP:@VW`$@SS75HGEQ1KD':FVN:\3-_IT8'WE3FLZ7
MQ!'>QT=N@2VC1>-J*?TK#U;5KFSO6AAV(JC.-N<U>TB\2\LT3<OF(-I!/)JW
M<V-M=E3-"CL!C=TQ19*7O(E>[+4Y8:]J(_C3_OFMW1+N6]LVEG?>X8CIBI/[
M$T__`)]Q^9JS;6D5G$T4*!%)S3G*+5D.31E^)O\`CQC_`.NE4?#H_P")@P[>
M5_6K_B;_`(\(_P#KI5#P[_R$3_UR_K37P#C\)N:F!_9ESQ_RSKBFX4_2NVU/
M_D%W/_7.N(;[IX[4Z!43?\.#_2+L>P_F:TM=`_LJ;IU%9OAS_CYO/H/YFM/7
M?^05-]12G\9+^(X_N"<8[UVFDQB+2[0+_P`\P?KG-<41QVZ5VVG#_B6VO_7%
M?Y&JK[#D4=;U6:QE6&WP)"-Q;'05@W6I75W&%E8-Y?(XQ5OQ!_R%3_NUEH`S
M@'H2,U5.*Y;@E[IV6EVB6>GHJJ2S#>Q[U5UC5GL)5MX8U:7&XL>PK8"A<*O`
M`'\JKSV%G/-YDEO&[8P20:P37-J1U.<.OZ@>\?\`WQ2'7K]@03'@CGY.U=#_
M`&1I_P#SYP_E3)=)L!#(5M(@0I(('3BK4X]BKHXWD*-PRPSG\:0C@T'/S8&%
M#$4'H:WZ&A]H>&O^15T?_KRA_P#0!11X:_Y%71_^O*'_`-`%%?(U/C8SXOH/
M2B@U]<([?3_^09:_]<DJT1GMG\*JZ=_R#;;_`*Y)63XAGF@GA".Z;E_A:N5*
M\C*UY'0;?]G]*7&.@QCO7"?;;K_GYD_.GP:E?0,K)</N]":T]DQ\IV=V9UMF
M:WC1IA]T$UQ$\DLMS(T^?,W?-N'2NV@<S6R3E"ID7=CTKGO$ENL=U%,J\2KA
MO^`U-)V=@CO8T]"_Y!,?U:J?BC_4P?[U7-!!.DQ\=VJGXH'[J#C^*G'^('VA
M/#4ZJ9H&'SL-ZBM75+,WMC+$@P^,K7&VTSVUPDT;8=6R0?2NOL=3M[Y%VL$E
M[HQY_P"`^M$XM.Z"4=;G&R1O&[(X967^\*U-"T^2XO5G*8BC.=S?Q5U+P12'
M+Q(Y]2M.<QPKEF6-%_O'%#JMJP<XCN(XG<G`5>I[UQ$<<E_?F-/O2R$Y'\-:
M6L:PLZFWMV_=Y^8_WJC\.HK:D7/\*$TXIQ5V-*RN;]IIMK91J$B4M_$[=35W
M&!P,#VI'.U6;&2`37$7.H7=S.9&E<`G@!L;:B*<NI*5SN,'WHP1R,@^M<%]I
MN/\`GO)_WU09YF_Y:R?]]57L/,?*=K<7EO:0M)+(@/\`<_B/X5QE]=M>WKS,
M"N_A#Z"H22W4DGU-'?\`&M(041K0%8HV5.T]>#BK(U2]5<"ZE7\0:W]`A633
M,O"K'>><9K4^SP_\\(_P2IE42=K!*1QW]KW[?=NI#[8%=/I'VIK)9+HN[L>`
M_&*NK;Q)]R%!^%1SW$-NF9I$1?\`:;FLY24E9(3=S(\2G%K`.[L:I^'?^0DW
M_7+^M5=3U'[?=AE&(8^%5N"?>K7AP'^T'XY\JM+6AJ%M+&[J?_(+N/\`<KBM
MK>A'_`:]!*Y&"N?PI/*7^X/RK.-3EZ`G8P/#=NZB>:0%4;H",$U=UYE72)">
MI8"K\CQP+F1@BCNQZ5S6N:E'<M%!"<Q(<D^I]:(WE*X;R,4]Z[C31_Q+;3_K
MDO\`(U0T&VBDTI6>*-\L>66M=454"*I11T`%.L[JP2EI8Y7Q%QJQ_P!VLK&3
MBN^:V@D;+P(Y]2M8GB*"*&TB9(U7+=`O6KISO[H1E?0U[>=9[6.=.3(H;'Z5
MC:Y-?VUT9(II5A*@97H#Z57T?5A:*;:X&82<JP_A]JZ2.2"Y0&-TD4CH#FH:
M<'<-G<XW^U;[_G[?_OK_`.M0=5O3]ZZ<@]1G_P"M79_9X_\`GFO_`'S4<\$8
MMY2(E^XW\/M351=@N<(2Q!W'.3FE/0TI'S-Q_$:0]#6[-#[0\-?\BKH__7E#
M_P"@"BCPU_R*NC_]>4/_`*`**^1J?&QGQ?0:*#TKZX1V^G?\@NS_`.N253U?
M2IM0EB>)U&U?XJ2RUBPAL8(Y+A494VMPU6?[9T[_`)^E_P"^&KF?-%W2,?>Y
MC%_X1J[_`+\7Y4Z/PU.73S)T"_[(K8_MG3O^?I?^^&IC:WIH_P"7G=_P!J?/
M/L/FD:"1JD:Q*N%5>]<YXGF1IH84^\B[FJW<>([=$98$:5O]JN9FFEFG:61M
MTK-NW55*#O>0XQUN:EEH]S>VRS1W*QH[;>AJ'4M.N+)(C+,LFYMORC-:FD:C
M96VG)'-*%DW;L;:K:_>6MW'`+>0,R-NX6G>7-L/4Q,=Z.AR.".GM1VHK4LG6
M]NE7:MQ*JCT;-,>>:9MTK.S>C-4>*"*!6#M6GH,ZQ:HF[Y0XVBLRE!(((Z@Y
M%*2NK$GH)`(Y%<[=>&F>4O;3!06+;66EL_$:;5CO(W/8.HK0&MZ<RY-SC_>2
MN:TX["Y7$Q_^$:N_[\7Y4?\`"-7?_/2+\JVCK.G?\_2_]\-1_;.G?\_2_P#?
M#5?//L+FD8O_``C-X>/.B_*LJ2-H)7C8@LC%3MKK_P"V=.S_`,?2_P#?+5R5
MVR/=S,C!HRY8$>]:0<GN7&_VB(2R(,`D?0TOG3?\]6_.FXHQ5E"^;+_ST;\Z
M"2?O$GZTE%`!CO2@E3E20?8XI**`'>=+_P`]6_.CSI?^>K?G3:,4"L*69ARQ
M/U-)CVHHIC'"61<J"P'3@UV^G\Z;:DG),*_R-<,1D8]:ZNSUBP2R@BEN%5E1
M0?D;T-95DWL1(RM?E=-4(#$#;V-91DD;AF)^IK1UNY@N]1\V!@R%<`A?2LRJ
MI_"./PB]O:E!*\J2/H<4E%44.\Z7_GJWYT&64@@R$CZTW%&*!6#M0>AHH/0T
M,9]H>&O^15T?_KRA_P#0!11X:_Y%71_^O*'_`-`%%?(U/C8SXOH-%!Z5]<(]
ME\-_!&RUWPWI^K2:U<PO>0+*8UB7Y=U:G_#/5C_T,%Y_WY6NX\((TOPFTM(U
M+.^E*JJO?Y*^;D\#^,-H!\.ZSG'/^CO7BTJU6I.:=7EL,[_7_@1J&G6,]YI6
MIK?N@W?9Y(=KGW5MWWJI^!?A):>+O"D>M/J\]LTK,OEQQ+_#7KWPVL-4TWP#
MI]KK"R+>)YA,<C?-&NYMJG\*I_"9H9?!#O!M^S-?W1BV_P!WS3M_2L98VLE)
M<U[.U["L?+*G<BMZC-+7M.G:+\&XKR#1FGN+V\+B$32/.%:3[O\`#M7K6/\`
M%?X<Z=X.MK34]):1;6>7R'@E?<4<*S*RM][^%J]2&-@Y*$DTWM<#R[WHP*]J
MT#P%X$T[PA%K/B>^2YG>W%Q)&MWM\M6&Y555;=NQ5CP[H7PE\:74NG:587L5
MVB%PKSS`X'=<NRFIEF%--V3:6[Z`>&]J*]&N/`%IHOQ<T[PU=/)=:?=%7`9B
MC/&VX$,R^ZUW7B7P-\,/"K6UUJZ7-O;R;D6W2>9S(WKP=WR_UIRQ]--))N^U
M@/G^BO;/''PT\-6_@[_A(O#J26ZJJ2A3+(ZS1MZAN5ZUMZI\+?`5CX<BU.]$
M^GQ(D4D]P+B1^#C(VMN^]TZ9YJ?[1I63L]78#YXQ17OF@>$OA1XO:XL]%AN&
MN84W,3+<*R@\;AO.WTK,O/!WPR\%71L_%&HW=Y>/ET3,H\M.W^KI_P!H0OR\
MKOVL!XM17N/B[X7^%CX)G\0^&5FMQ%!]H3]X[I,@Y(*O\U8_P]\`^%=4\.G6
M_$M^A+%BMM]K\H*J]SC#9H6/I.#G9^G4#R:C%>U:79_!C7]7BTFQL[L74[;(
MBTUP`S>QWUSOQ"^&J>&=>TVWTF21[74I!'$LIW/%)GH#W'>JAC82ERR35^X'
MF]'%>^7GPV^'W@G1X;GQ3+<7$DC>7YADE`=\9(58N?SI^D_#_P"&GC;3KEO#
MRW<,D)V/(DLV8W(R#B0D'\*AYA3M?E=N_09X!17HWA'X9-K7C'5='U*X=+32
MI-DYC7!D)/RA3[]3[5U&IZ?\%M!U*?2]06<W=NVV4"6Y;:1_NG;WJIXZFFHQ
M3?H(\1HKV7QM\+]`@\(OXG\+32BWCC6;8\A=)(R>JD_,#S5O0/AOX8O_`(6)
MKT]C(=1:Q><2K<R`!PIQ\H;':CZ_2Y5+SL,\0H^AP>QK>\$:7:ZWXTTC3K]#
M);7,VR1`^"1M8]N>HKT7Q[X*\%^$O$'A[=:RVVE7,CB^/GR.2H''5L]?3FM*
MN+A"?L[.XCS-_"NOQZ<=3DT:]2R$8D\_;\H0]_Q-8QP%)(X`Z5]=W_\`PCG_
M``KUA<F3_A'3:KD@R;O*XQ_M>GO7B/BQ/A2/#5W_`,(U)-_:J@>2&-QUSS]_
MY>E<^'Q[G=.+^7Z]AV':I\,-*T[P&^OQZ_YERELD_P!G^3EB0,9'/1J\Q[5[
MAKOPZ\,V/PHEUV#3Y5U!;&.<2&YD;#,5W?*6V\@TSPW\+/#-EX07Q%XNFE=6
MB$\B(YC2)3]W[G))!%32QD8Q;DV];;`>)48KWG0O#OP@\5WKZ=I%O<&[VEL>
M=<*<#ODG!K@/%/@`:!\0;3PZEZ/LMZ8Y(IYR%V1EBIWD\$C!Q713QM.4G%II
M^8K'"XP*,9X]>*]UU;PM\)_!UC;?VLTU_+(WEATNG:1B!GD1LH`Z5/IGPZ^'
M?CG0I[KPTMY9LCF(2&21MDFT'!#E@1@KTK/^T*>[B[=[`<!\-O`-OX\?4Q/?
M3V@M?*?:B9SO+<Y_X!7->*]#C\.>)[[2(YGF2UD\L2.N,\9KUSX"VLEEJ?BN
MTF`$L#P1R?+M^8-+S^(K//@FV\:_&OQ%;7\LB6=L1+(L9PSY(`&?0UE'%N->
M;<O=2"QXWVI:]N\1Z?\`"#POJ\FE:EIM])>1@-($EG.`WS`_?`[]A6;XN\&_
M#^3PI-J_AC5[>"Z2$7"6SWPD,B]UV,VX-V^M;0Q\9-7BTGUMH!Y%0>AHH/0U
MW,#[0\-?\BKH_P#UY0_^@"BCPU_R*NC_`/7E#_Z`**^1J?&QGQ?0>E%%?7"/
MK3P5*UM\+=&N``S1Z;'(N?\`<KR-?V@_$14'^R=)Y'I)_P#%5S5G\4O%>FZ/
M%HD5W;I;0P^0D9M58^7C^]]*XP+@#':O+H9?'GFZJO?8+GH6N_&3Q5K5C)8[
MK*QAF#K(UK&VXK_O,S?^.UZU\%ACX96W_7>;^=?,==?H?Q(\4>%]'73M-N+>
M.T1V**]NK'/\57B<%S4N2DDM;@<_X9_Y&#2/^OJ+_P!"6O?/V@!GP;I@/0ZF
M@/\`W[DKYYM)YK&[MY[=]LL,BLF?[W\-=)XE\?>(?%6G16>M7,4MO#,)E`@5
M#NVL/X?]DM55\-.=2$H[+<+GT!/:P>!/`JW?AGP\FH7,<,8$5O'^\G!VY=BJ
MEF_O5F^"?%.L^(_$)_M;P0VF&.)F2^>W>/:<\IN9>]>.:-\4_%N@:=%:VNHI
M+:PC:B74"OL']T,/F_.K;?&;QO+=QN-1MT(Z1+:KM;_>KC>`JZJR=^MPN=[X
MN_Y.'\-?]>\7_H<E4/VAA^]\/\=IOYI7G%[XX\0:AXEM_$5U-&VH62+&DJPJ
M$7EBN5_BY-0^*?&6M>*S:G7)HI#;[O)(@5-H;&?N_A6U'!U(5(2=K+<+E,Z]
MK$ULEA-J]^]D<1^0;AC'M!^[MW;:^A/BJ/\`BS4W_7.V_FM?-`X8,.HYKK-7
M^(WB7Q!H;Z+>W-O+:,$#*MLJ-A<;>?RKHQ&%E.I"4+63NPN=;^S]_P`C9J?_
M`%X_^U!61\;./B3<_P#7K%_6N8\,^*=5\*W<]YHLRI--%Y;LT*OP&']ZJ_B#
M7M1\1:O)J&J2JUVZJC,L2ID?\!H5"?UEU>EK!<^B(./@*3V_LD_R-0?#O1=.
MT7X:6FL:=I:7NI2VS3L57][,V3A`W;IC%>,#XE>)(?#O]@?:K=;'[.8#']F4
MML.<_-4?AKX@>)?"]J+/2M0;[.YWK#+$L@S[%N5KC>!JN,DGUOZA<]?T+QKX
MB\0^)+"TU7X?2P6QE'^DR6T@^S$9^?<Z;>/;UJ3XL74=KXB\&SRL%CCO\L3V
M[5YE/\9O&TQ1AJ$$*J<G9:IS^=8/BCQOKWBO[-'K5S'(+9BT16$(<X_V:J&!
MJ^T4FDEZA<]L^-V@:MKNA::VE6$]XT%P[21P1[W`*8R!7#>!?A+J^L07<VIS
M:CH>UAY2M#M9^.NUNE86E?%GQCHT"6L>I+/%&FV-+J!7P/3<,-^;&I;_`.,/
MC6[MGA;4(+9&!#-!;+N/XFJAA\53@Z4&K=PN>C?".V@TSQ+XLT9+MKF2WG7$
M[_>D4<;C^.:L^)/%WC72M>N[.R\#+?6BR'R+E()'$B>Y48!KP+2M8U/1]234
M-/O)H+P,1YJD$DGDY!X-=JOQM\:P1[9+JS<CC?):KN/X+Q2JX&I[1S5I:==/
MR"YZ?XHN?%T_PZU&XU.UT6RMGLLRP_O/,CSC(Y^7TJ[X(A>\^"MM!;+OEDT^
M1$4=2VT@#\Z\(\0_$'Q/XJMA9ZGJ`:W(W>1#$J(<=V[FF>&O'7B7PS;-!I%Z
M5LV.3!+&LD8/J`>1FI^H5?965D[W"YTOPU\#^);;QYI=W=Z+>6MM9R;YI;B+
MRUQM88'][D]:Z;]H;[NA]^)?Z5Q-W\7_`!M=O&YU*.`1'>$@MT`;ZYZBL;Q1
MXRUOQ;):IK<\4GV<MY6(53KU^[6T</7E652I;0+GO][;3ZK\$%@LH9+B>;2X
M_+CC&6?[IX'K7F$/PA*>`)_$&K7UU87<4$DK6<EO@+C[H.[G)XKGM$^)OBKP
MOIZ6%E>HUM&,I'<Q"3:,_P`)Z@>U,\0_$7Q5XFLFM-1OD%FY!:&VA6-9/<G[
MQQZ=*SIX7$TY-0:LW<+GMOBG/_"A)L#G^S(?YI4OB.TG\0_!)X-(C:YFGL(6
MACC/,@#*W'J<`UX9=?$GQ)?>'6T&XN;9K!H%A91;*&"+@CFF>&_B!XI\,6RV
M6E7["V`+BVEC21%'J"W(^E9K+ZUN96NG<+FKX/\`AEX@UC7S;W]IJFC0!&)N
MVMFC.<],]ZV#X$T_3_C!HGA^^U*758)8S/,MP,=%=EC(W'(X!Q_M5ES_`!K\
M;31E1=6D`QRR6PS7&3ZOJ=SK0U2:\N'U/S1()R^6#CG*GL/:NE4<5.3YVDO(
M+GTGXT\0ZGX.CM+3P_X/-_;R+AV@A8QQ@=`51:T?`.HWFK:3<7U_X:.A74ER
M0\1B,?G?*N),%0?;G^[7AMM\:/&T,:Q?;+:9@,!I+9=WU)[TQ?C)XXB>4G48
MW!8DAK2/"C':N1Y=6Y>6ROWN%ST3X/?\CCX\X_Y?$_\`1DU9NFPZVWQQ\3S:
M%<:>LT2@S0WH<)+'A.05[AL5YOH'C_7_``Y>:IJ&GR6XEU&42W+RP*06RQ&`
M.G+-5-O%VM'Q9-XCM[PP:I*V]I+=0JD'C!4\'Z&ME@JKE)Z:JP7/=]>\=^)=
M$U5]/G\!3:HJ!66YM#(T;D]0/W+=/K_#5C6M$TKQ9\.+K4]4\.1Z5>_8I9D6
M2,+-:LJL1E@%..,X/7TKR@?&[QK&@5[FQ..-TEL,GW^6LC7OB/XL\36$EK?Z
MB19O_K(8(UB5O0$CYB/8U$<!6YDTDK=;L+G(GC=MRWS%05Z$#O0>AHQQ0>E>
GRP/M#PU_R*NC_P#7E#_Z`**/#7_(JZ/_`->4/_H`HKY&I\;&?__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
